analyst
EL
NASDAQ · ELTX
Elicio Therapeutics, Inc.
Healthcare · Biotechnology
$1.99
Down-$0.01 (-0.50%)
Updated Sep 16, 2026, 6:44 AM
SID Score
2.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 144.37M
- P/E ratio
- -3.04
- Dividend yield
- 0.00%
- 52-week range
- $1.95 – $16.00
- Volume
- 319.02K
- Avg. volume
- 97.45K
Price performance
ELTX price history
1M range · 20 trading sessions · Daily adjusted prices
ELTX closed at $1.99 after 20 trading sessions, down 36.01% for the selected period.
- Last close
- $1.99
- Period change
- -36.01%
- Period low
- $1.99
- Period high
- $3.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.01 | $2.02 | $1.915 | $1.99 | 319.02K |
| Sep 14, 2026 | $2.06 | $2.0899 | $1.95 | $2.00 | 391.83K |
| Sep 11, 2026 | $2.14 | $2.20 | $2.02 | $2.05 | 445.8K |
| Sep 10, 2026 | $2.17 | $2.20 | $2.07 | $2.11 | 343.24K |
| Sep 9, 2026 | $2.37 | $2.375 | $2.17 | $2.18 | 459.08K |
| Sep 8, 2026 | $2.42 | $2.46 | $2.34 | $2.35 | 324.72K |
| Sep 4, 2026 | $2.50 | $2.50 | $2.36 | $2.41 | 487.92K |
| Sep 3, 2026 | $2.55 | $2.56 | $2.465 | $2.50 | 272.71K |
| Sep 2, 2026 | $2.57 | $2.61 | $2.48 | $2.55 | 397.65K |
| Sep 1, 2026 | $2.70 | $2.71 | $2.55 | $2.56 | 334.84K |
| Aug 31, 2026 | $2.84 | $2.8699 | $2.70 | $2.70 | 412.19K |
| Aug 28, 2026 | $3.00 | $3.00 | $2.84 | $2.84 | 421.56K |
| Aug 27, 2026 | $3.00 | $3.05 | $2.97 | $3.00 | 131.24K |
| Aug 26, 2026 | $3.00 | $3.07 | $2.96 | $2.98 | 182.66K |
| Aug 25, 2026 | $3.00 | $3.095 | $2.9804 | $3.01 | 223.61K |
| Aug 24, 2026 | $3.06 | $3.06 | $2.94 | $2.98 | 311.99K |
| Aug 21, 2026 | $3.11 | $3.11 | $3.03 | $3.04 | 279.37K |
| Aug 20, 2026 | $3.11 | $3.135 | $3.02 | $3.075 | 207.77K |
| Aug 19, 2026 | $3.34 | $3.36 | $3.04 | $3.13 | 502.61K |
| Aug 18, 2026 | $3.03 | $3.12 | $2.98 | $3.11 | 389.1K |
Latest ELTX news
The latest Smart Investors Daily articles mentioning ELTX.
Stock researchCompany · Overview
ELTX research
Overview
Company profile and research snapshot.
Company profile
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 16, 2026 | Jones Trading | Hold | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 10, 2026 | B. Riley Securities | Buy | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.